Which Policies for Vaccine Innovation and Delivery in Europe ?

Mathias Dewatripont

No 2022-14, Working Papers ECARES from ULB -- Universite Libre de Bruxelles

Abstract: This paper analyzes the subsequent steps of the covid vaccine experience in the European Union. It stresses the features of the US innovation ecosystem which were responsible for its success. It argues that the European Union did reasonably well in procuring vaccines and logistically organizing their delivery but that vaccine hesitancy proved to be a key constraint. The paper discusses European countries’ vaccination strategies and their plusses and minusses. Finally, it draws some lessons for dealing with the tradeoff between drug and vaccine innovation and affordability, an issue whose importance is bound to grow with promising but costly scientific advances.

Keywords: vaccine innovation; covid-19; innovation ecosystem; vaccine hesitancy; drug prices; European health policy (search for similar items in EconPapers)
Pages: 22 p.
Date: 2022-05
New Economics Papers: this item is included in nep-eur and nep-ino
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Published by:

Downloads: (external link)
https://dipot.ulb.ac.be/dspace/bitstream/2013/3432 ... T-which-policies.pdf Œuvre complète ou partie de l'œuvre (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eca:wpaper:2013/343280

Ordering information: This working paper can be ordered from
http://hdl.handle.ne ... lb.ac.be:2013/343280

Access Statistics for this paper

More papers in Working Papers ECARES from ULB -- Universite Libre de Bruxelles Contact information at EDIRC.
Bibliographic data for series maintained by Benoit Pauwels ().